T
he emergence of drug-resistant strains of Mycobacterium tuberculosis was documented soon after the first tuberculosis (TB) drugs became available in the late 1940s (1) . The observation that this could be minimized with adherent, quality-assured multidrug therapy provided strong motivation for the implementation of the DOTS (directly observed therapy, short course) strategy in the early 1990s (2) . The strategy aimed to achieve global TB control through microscopic diagnosis of infectious cases, standardized multidrug therapy, a reliable supply of quality-assured drugs, and ensuring treatment adherence through directly observed therapy (DOT). Worldwide implementation of the strategy has cured some 50 million patients and averted 7 million deaths compared to pre-DOTS standards (3) but has been unable to stem the disconcerting rise of drug-resistant TB.
Descriptions of the "fitness cost" associated with the acquisition of drug resistance (4) may explain why public health specialists failed to appreciate the potential for epidemic spread of drugresistant TB. Limited resources, an absence of laboratory infrastructure, and unavailability of second-line drugs motivated the DOTS strategy's select focus on sputum smear-positive cases and treatment with standardized first-line regimens. Despite intermittent reports of patients with drug-resistant TB, the expectation was that these would disappear once program performance improved and the proverbial "tap was turned off." Sustained epidemic spread of drug-resistant TB was considered unlikely (5) . However, the description of a large cluster of extremely drugresistant TB (XDR-TB) cases in South Africa provided stark evidence that some drug-resistant strains are highly transmissible, at least among immunocompromised patients (6) , similar to an earlier outbreak of multidrug-resistant TB (MDR-TB) in New York City (7) . This prompted a prominent focus on drug-resistant TB in the revised Stop TB Strategy (8) , with a clear description of the critical steps required for its prevention and control (9) .
The global burden of drug-resistant TB remains poorly quantified. The World Health Organization (WHO) estimated that in 2011, approximately 630,000 (5.3%) of the 12 million prevalent TB cases were MDR-TB (10) . Only a small fraction of reported cases (Ͻ20%) were correctly diagnosed, and even fewer were treated according to WHO standards. This reflects major structural, economic and political constraints (11) . More than 80 countries have reported cases of extremely drug-resistant (XDR)-TB (10) , and the drug-resistant TB disease burden in subSaharan Africa is likely to be grossly underestimated (12) . Southern Africa is the epicenter of the dual human immunodeficiency virus (HIV)/TB epidemic, which has been associated with high rates of drug-resistant TB (10) . These alarming figures emphasize the need for improved epidemiological understanding, including better descriptions of the molecular epidemiology and transmission dynamics of MDR-TB.
Molecular tools provide the means to assess the evolution and spread of M. tuberculosis. High-resolution methods demonstrated the important contribution of exogenous reinfection to TB recurrence, especially in areas where TB is endemic (13) . Geospatial mapping of case clusters and whole-genome sequencing combined with detailed social network analysis have been used to guide public health responses (14) . Spoligotyping provides a simple standardized method of strain typing and has enhanced our understanding of global strain distribution (15) . Strains of the Beijing genotype have a very distinct spoligotype, but this monomorphic signature reduces spoligotyping's discriminatory power. Additional genetic markers such as multiple interspersed repetitive unit (MIRU) typing provide enhanced resolution (16) . Although molecular typing is routinely performed in most developed countries (17) , it is rarely done in areas of TB endemicity, where the information would be most useful.
High and rising rates of drug-resistant TB have been recorded in South Africa, with some well-defined clonal outbreaks (6, 18) . However, strain diversity among MDR-TB cases has not been assessed in Johannesburg, the country's most populous city and cultural melting pot. We aimed to perform a detailed molecular epidemiological assessment of MDR-TB cases within the greater Johannesburg area and to evaluate evidence for epidemic spread within the study setting.
MATERIALS AND METHODS
Setting and study design. Johannesburg's population exceeds 3 million people, with nearly 50% being under 35 years of age, and is growing at an estimated rate of 4.1% each year (19) . People migrate to Johannesburg in search of jobs and better living conditions from all over Africa; many reside in low-cost informal settlements that are plagued by overcrowding and poverty. This retrospective descriptive study included isolates from all MDR-TB patients (first MDR isolate) identified at the National Health Laboratory Service (NHLS) Central TB laboratory in Johannesburg, from March 2004 to December 2007. Sputum samples were submitted from over 100 hospitals and clinics. Limited demographic data were obtained retrospectively from laboratory records; HIV infection status was not recorded. The NHLS Central TB laboratory processes the vast majority of sputum samples in Johannesburg.
Sample processing. Mycobacterial growth indicator tube cultures (Bactec MGIT 960; Becton Dickinson BioSciences, Sparks, MD) were obtained, and a heat-killed aliquot was collected for spoligotyping and MIRU typing. Sample processing was performed in a biosafety level 3 laboratory using standard procedures. Drug susceptibility testing (DST) was performed per physician request. Guidelines advised testing of all retreatment cases and treatment failures, but adherence to these recommendations was not monitored. Resistance against all first-line drugs, excluding pyrazinamide (PZA), was assessed using the indirect proportional method in Bactec MGIT 960 tubes for isoniazid (INH) at 0.1 g/ml, rifampin (RMP) at 1.0 g/ml, ethambutol (EMB) at 5.0 g/ml, and streptomycin (S) at 1.0 g/ml.
Spoligotyping was performed according to the manufacturer's instructions using membranes and equipment provided with the spoligotyping kit (Isogen; Bioscience BV, Utrecht, The Netherlands) (20) . PCR amplification was performed using an iCycler Thermocycler (Bio-Rad, Hercules, CA). This genotyping method determined the presence or absence of 43 direct and variable repeat sequences with the direct repeat region, thereby generating spoligotype signatures which were characteristic of defined strain genotypes (21) . In addition to spoligotyping, all strains were typed by 12-locus multiple interspersed repetitive unit typing (12-MIRU) using standard methods (16, 22) , and 24-MIRU was performed on all Beijing genotype strains (22) . This method determined the number of repeat sequences present at each allele, thereby generating a numerical profile for each strain. Results were compared with the SITVIT2 proprietary database of Institut Pasteur de la Guadeloupe, which is an updated multimarker version of previously released SpolDB4 (23) and SITVITWEB (24) databases. In this database, spoligotype international type (SIT) and MIRU international type (MIT) designate spoligotypes and MIRU patterns shared by 2 or more patient isolates, respectively, whereas "orphan" designates patterns reported for a single isolate. Major phylogenetic clades were assigned according to signatures provided in previous versions (23, 24) .
Statistical analysis. Cluster analysis was performed for spoligotyping alone and in combination with 12-MIRU typing. A cluster was defined as two or more strains with identical genetic patterns. The clustering rate was calculated as (number of clustered cases Ϫ number of clusters)/total number of cases. The discriminatory value of various strain typing methods was calculated using the Hunter Gaston discriminatory index (HGDI) (25) :
where N is the total number of strains in the typing scheme, s is the total number of different patterns, and n j is the number of strains belonging to the jth pattern. This method was also used to assess the individual contribution of each of the 24-MIRU loci to discriminate between Beijing genotype strains. For Beijing genotype strains, a minimum spanning tree was built with 12-and 24-MIRU profiles using BioNumerics software (version 3.5; Applied Maths, Sint-Martens-Latem, Belgium) to reflect likely evolutionary relationships. Ethics approval was granted by the University of the Witwatersrand Human Research (Medical) Ethics Committee (no. M050628).
RESULTS
A total of 434 MDR-TB patients were identified and included in the study. matched pre-existing shared types, and 5 (11 cases) were newly created, as they matched existing orphan types in the SITVIT2 database [SIT2996 (n ϭ 2), SIT2997 (n ϭ 6), SIT2998 (n ϭ 1), SIT2999 (n ϭ 1), and SIT2196 (n ϭ 1)]. Beijing genotype strains were most common, although they represented only 16 Beijing genotype strains were further differentiated using 24-MIRU, which facilitated a more detailed phylogenetic reconstruction relative to the 12-MIRU method (Fig. 1) . It also increased the resolution from nineteen 12-MIRU profiles (64 clustered and 7 unique) to thirty-four 24-MIRU profiles (52 clustered and 19 unique) (Table 3 ). Most unique strains were very similar to clustered strains, with only minor (1-allele) differences. Overall, 24-MIRU provided improved discriminatory power (HGDI, 0.97) compared to 12-MIRU (HGDI, 0.90). Regarding Beijing strains specifically, Table 4 reflects the discriminatory value contributed by each of the 24 loci. 12-MIRU included 4 loci with moderate discriminatory value. A previously proposed 15-locus combination (22) included 7 loci with moderate to high discriminatory value, while 24-MIRU included 9 loci with moderate to high discriminatory value. The loci MIRU2, MIRU4, MIRU20, MIRU23, MIRU24, MIRU31, and ETR-B demonstrated no variability for Beijing genotype strains.
DISCUSSION
The clustering rate of 66.8% obtained by using a combination of spoligotyping and 12-MIRU typing, which has a discriminatory power similar to that of classic IS6110 restriction fragment length polymorphism (RFLP) fingerprinting, indicates frequent MDR-TB transmission in the greater Johannesburg area of South Africa. The large diversity of MDR-TB strains and the multiple clusters identified indicate that this is not an isolated clonal outbreak. It reflects transmission from numerous source cases, confirming true epidemic spread of MDR-TB within the study community. These findings support modeling studies that predicted the likely emergence of highly transmissible MDR-TB strains over time (26) . Given the slow and highly variable rate at which M. tuberculosis infection generates secondary cases (27) , it is likely that transmission events were underestimated in the 3-year snapshot provided by this study. Selection and amplification of drug resistance are facilitated by exposure to poor-quality drugs, suboptimal regimens, and poor treatment adherence, but may occur even in well-functioning TB control programs (26) .
Studies on clinical MDR-TB strains have demonstrated that the fitness cost associated with acquired drug resistance can be overcome by various compensatory mechanisms (28) . The opportunity for compensatory evolution is enhanced by ongoing selective drug pressure, especially with poorly targeted therapy. This allows the best-adapted drug-resistant strains to regain (or even exceed) full fitness (28) . Use of a standardized retreatment regimen remains common practice in many areas where TB is endemic, despite the fact that the addition of a single agent (streptomycin) in patients with TB treatment failure or relapse encourages multiplication of resistance (29) . Failure to perform DST leads to poorly targeted treatment and bad outcomes despite adequate treatment adherence (29) , with ongoing selection of the fittest drug-resistant strains. The fact that the majority of clustered MDR strains were resistant to multiple first-line drugs indicates primary transmission of these strains. Early diagnosis and rapid initiation of effective treatment is essential to control the TB epidemic, especially in communities with high infection pressure (30) . The diagnosis of young children with culture-confirmed MDR-TB provides further support for ongoing transmission within the study community (31) . Children with MDR-TB are likely to have been underrepresented, given the need for admission to a referral hospital for adequate diagnostic work-up, which limits diagnostic access in most resource-limited settings (31) . High rates of MDR-TB has been documented in children from Johannesburg recruited into a prospective INH preventive therapy trial in HIV-exposed infants, confirming transmission within HIV-affected households (32) . Importantly, it has been postulated that drug-resistant strains with reduced fitness may be more readily transmitted in settings with a high HIV prevalence (33) . Rising numbers of children diagnosed with drug-resistant TB in Cape Town, suggests increasing transmission rates in other parts of South Africa as well (34) . No major gender-related differences were observed, but the young average age of adult TB patients (especially women, 33.8 years) is consistent with pronounced shifts in the age and gender profile induced by heterosexual spread of HIV infection (35) .
The strain diversity observed is broadly consistent with studies from other parts of South Africa (36, 37) , probably reflecting extensive population mixing. Interestingly, LAM11-ZWE (SIT59), which predominates in neighboring Zambia and Zimbabwe, was rare (38) , with common strains in other parts of Africa being totally absent. This is surprising given the huge number of African immigrants that are resident in townships surrounding Johannesburg. The dominance of locally circulating strains may indicate that imported strains struggle to replace "resident" strains, but it may also reflect some selection bias, since immigrants are required to present a valid visa to access expensive second-line TB treatment services. The high prevalence of SIT60 (LAM4/F15/KZN), the strain responsible for the XDR-TB outbreak in KwaZulu Natal Province (6), reflects long standing labor migration patterns between KwaZulu Natal and gold mines in Johannesburg. This strain has already demonstrated the capacity to acquire additional secondline resistance (and retain fitness to cause outbreaks), which provides a stark warning to the public health community (39) .
The Beijing genotype, which has a well-documented association with transmitted drug resistance (40) (41) (42) (43) , was most prevalent. Its ability to replace resident strains was demonstrated in a community-based study in Cape Town that prospectively tracked the rapid emergence of Beijing genotype strains over a 12-year period (44) . The success and global spread of the Beijing genotype has been ascribed to multiple factors (45) , including resistance to Mycobacterium bovis BCG-induced immunity (46) , potential hypervirulence, and reduced fitness costs associated with the acquisition of drug resistance (47) . The resolution of Beijing genotype strains was enhanced by 24-MIRU typing relative to the 12-MIRU typing. This facilitated detailed mapping of likely transmission clusters (Fig. 1) , while the identification of minor variants suggests that that these strains have been in circulation for an extended period and have become endemic in the region. Pronounced differences in the size of transmission clusters suggest highly variable strain-related transmissibility, even among highly monomorphic Beijing genotype strains. Improved understanding of the factors that determine the transmissibility of particular strains has high public health importance.
The study was limited by selective sampling, since only specimens for which the physician requested DST were eligible for inclusion. Differential testing could have biased clustering estimates, especially if physicians were more likely to test contacts of known MDR cases or if specific facilities where transmitted (pri- mary) MDR-TB was more of a concern were more likely to request DST. In addition, retreatment and HIV infection status, total case numbers processed by the laboratory, and strain diversity among non-MDR strains were not available in this retrospective analysis, and these data would have provided important epidemiological context. However, although cluster rates may have been influenced by biased sampling, the observation that MDR-TB is regularly transmitted within the study community remains valid and has key public health importance. In summary, this analysis of MDR strains identified in routine clinical practice provides convincing evidence of true epidemic spread of MDR-TB in Johannesburg, South Africa. It indicates that simply "turning off the tap" through improved programmatic management of drug sensitive TB is insufficient to contain the spread of drug-resistant TB, although it remains important. New strategies should include early accurate diagnosis and effective treatment of all MDR-TB cases, as well as consideration of creative public health approaches to reduce TB transmission within identified "transmission hotspots" (48, 49) .
